Floatz logo

Sasanlimab

Part 1

Pfizermonoclonal_antibodyPhase 1Dormant
D
31/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
16/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Part 1 cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Sasanlimab is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
renal cell carcinomaDormant
C
Indicative ·
39 / 100
View asset →
neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →